PMS-LITHIUM CARBONATE - CAP 300MG 300 MG
LITHIUM CARBONATE : 300 MG · DIN 02216140 · PHARMASCIENCE INC
Health Canada status: DORMANT
What is PMS-LITHIUM CARBONATE - CAP 300MG?
PMS-LITHIUM CARBONATE - CAP 300MG 300 MG contains LITHIUM CARBONATE : 300 MG. It is listed in the Health Canada Drug Product Database under DIN 02216140, held by PHARMASCIENCE INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as dormant, status dated 01-Aug-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02216140 |
|---|---|
| Brand name | PMS-LITHIUM CARBONATE - CAP 300MG |
| Generic / active ingredient | LITHIUM CARBONATE : 300 MG |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 300 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AN01 LITHIUM |
| AHFS class | 28:28.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 01-Aug-2025 |
| Original market date | 1996-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02216140 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2216140 |
| Brand name | PMS-LITHIUM CARBONATE - CAP 300MG |
| Active ingredient / INN | LITHIUM CARBONATE : 300 MG |
| ATC code | N05AN01 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N05 |
| AHFS class | 28:28.00 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PHARMASCIENCE INC |
Which pack is which?
| Strength on the label | 300 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code N05AN01 LITHIUM. 7 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LITHIUM CARBONATE | 150 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02242837 |
| CARBOLITH | 150 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 00461733 |
| CARBOLITH | 600 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | MARKETED | DIN 02011239 |
| LITHANE | 150 MG | CAPSULE | SEARCHLIGHT PHARMA INC | MARKETED | DIN 02013231 |
| LITHANE | 300 MG | CAPSULE | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00406775 |
| LITHMAX | 300 MG | TABLET (EXTENDED-RELEASE) | AA PHARMA INC | MARKETED | DIN 02266695 |
| PMS-LITHIUM CARBONATE - CAP 150MG | 150 MG | CAPSULE | PHARMASCIENCE INC | MARKETED | DIN 02216132 |
| APO-LITHIUM CARBONATE | 300 MG | CAPSULE | APOTEX INC | DORMANT | DIN 02242838 |
| CARBOLITH | 300 MG | CAPSULE | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00236683 |
| DOM-LITHIUM CARBONATE | 150 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED PRE MARKET | DIN 02231397 |
Who else supplies LITHIUM worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LITHIUM appears in 7 registered pack listings across 6 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.